Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NUVL 
Nuvalent Inc (NUVL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NUVL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $116.91
1 Year Target Price $116.91
| 8 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.56% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.52B USD | Price to earnings Ratio - | 1Y Target Price 116.91 |
Price to earnings Ratio - | 1Y Target Price 116.91 | ||
Volume (30-day avg) 11 | Beta 1.3 | 52 Weeks Range 55.53 - 113.51 | Updated Date 08/29/2025 |
52 Weeks Range 55.53 - 113.51 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.92 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -1.22 | Actual -1.39 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.37% | Return on Equity (TTM) -43.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4475811708 | Price to Sales(TTM) - |
Enterprise Value 4475811708 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -22.26 | Shares Outstanding 66669600 | Shares Floating 41562670 |
Shares Outstanding 66669600 | Shares Floating 41562670 | ||
Percent Insiders 2.83 | Percent Institutions 109.14 |
Upturn AI SWOT
Nuvalent Inc
Company Overview
History and Background
Nuvalent, Inc. is a biotechnology company focused on developing precisely targeted therapies for cancer. Founded in 2017, it has rapidly advanced its pipeline through clinical trials, focusing on overcoming resistance mechanisms in cancer.
Core Business Areas
- Kinase Inhibitor Development: Nuvalent's core business is the discovery and development of selective kinase inhibitors to address drug resistance in cancer. Their focus is on developing therapies that target specific kinases, while sparing other kinases to minimize side effects.
Leadership and Structure
Nuvalent is led by a team of experienced biotech executives and scientists. The organizational structure is typical of a biotech company, with research and development, clinical operations, and business development functions.
Top Products and Market Share
Key Offerings
- NVL-520: NVL-520 is a novel ROS1-selective inhibitor designed to address limitations of current ROS1 inhibitors in patients with ROS1-positive non-small cell lung cancer (NSCLC) and other solid tumors. As a clinical-stage asset, exact market share is premature, but its potential is significant as current ROS1 inhibitors face resistance issues. Competitors include Rozlytrek (entrectinib) by Roche and Xalkori (crizotinib) by Pfizer. Potential peak sales estimated at $1B+ (analyst estimates).
- NVL-655: NVL-655 is an ALK-selective tyrosine kinase inhibitor (TKI) designed to specifically target tumors that have developed resistance to currently available ALK inhibitors. Similar to NVL-520, it's in clinical development, and market share is not yet defined. Competitors include Alecensa (alectinib) by Roche and Zykadia (ceritinib) by Novartis. Potential peak sales estimated at $1B+ (analyst estimates).
Market Dynamics
Industry Overview
The oncology drug market is a large and rapidly growing market, driven by increasing cancer incidence and advances in cancer treatment. Precision medicine, including targeted therapies, is a key trend.
Positioning
Nuvalent is positioned as a precision oncology company focused on developing highly selective kinase inhibitors to overcome resistance mechanisms in cancer. Their competitive advantage lies in their focus on selectivity and addressing unmet needs in specific patient populations.
Total Addressable Market (TAM)
The TAM for targeted oncology therapies is estimated to be in the tens of billions of dollars annually. Nuvalent is positioned to capture a portion of this market with its pipeline of selective kinase inhibitors, targeting specific patient populations with high unmet needs. Analyst estimates suggest potential multi-billion dollar peak sales across their assets.
Upturn SWOT Analysis
Strengths
- Highly selective kinase inhibitors
- Experienced management team
- Strong preclinical and clinical data
- Focus on addressing drug resistance
- Robust pipeline of targeted therapies
Weaknesses
- Clinical trial risks
- Reliance on successful drug development
- Competition from established pharmaceutical companies
- Limited commercial infrastructure
Opportunities
- Expanding indications for existing programs
- Partnering with larger pharmaceutical companies
- Acquiring complementary technologies
- Advancing additional pipeline programs
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from novel therapies
- Patent challenges
- Pricing pressures
Competitors and Market Share
Key Competitors
- ROSE
- PFE
- NVS
Competitive Landscape
Nuvalent competes with established pharmaceutical companies in the oncology space. Its competitive advantage lies in its focus on selectivity, addressing drug resistance, and developing novel therapies for specific patient populations. The others such as ROSE, PFE, NVS are well established but not completely specialized in Kinase resistance.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the advancement of pipeline programs and successful fundraising activities.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates suggest significant revenue potential upon commercialization of key assets.
Recent Initiatives: Recent initiatives include initiating and advancing clinical trials for NVL-520 and NVL-655, presenting clinical data at scientific conferences, and securing partnerships.
Summary
Nuvalent is a clinical-stage biotech company with a promising pipeline of selective kinase inhibitors. The company's focus on addressing drug resistance in cancer is a key strength. However, it faces significant clinical trial risks and competition from larger pharmaceutical companies. Successful clinical development and regulatory approvals are crucial for its future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may be subject to change. Investment decisions should be made based on individual risk tolerance and financial circumstances.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nuvalent Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2021-07-29 | CEO, President & Director Dr. James R. Porter Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 200 | Website https://www.nuvalent.com |
Full time employees 200 | Website https://www.nuvalent.com | ||
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.